jofinЖурнал инфектологииJournal Infectology2072-6732IPO “АIDSSPbR"10.22625/2072-6732-2011-3-3-52-55jofin-41Research ArticleОригинальные исследованияOriginal ResearchJustification of the program therapy of acute hepatitis CJustification of the program therapy of acute hepatitis CМихайловаЕ. А.MikhailovaE. A.

доцент кафедры инфекционных болезней Нижегородской государственной медицинской академии, к.м.н.; тел.: 8(831)433-44-46

mikhailov-leto@yandex.ruСоболевскаяО. Л.SobolevskayaO. L.

доцент кафедры инфекционных болезней Нижегородской государственной медицинской академии, к.м.н.; тел.: 8-910-396-91-37

vad5584@yandex.ruНижегородская государственная медицинская академия, Нижний НовгородРоссияNizhegorodskaya State Medical Academy, Nizhniy NovgorodRussian Federation201106092014335255Copyright © Михайлова Е.А., Соболевская О.Л., 20142014Михайлова Е.А., Соболевская О.Л.Mikhailova E.A., Sobolevskaya O.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.niidi.ru/jofin/article/view/41

Treatment of acute hepatitis C remains one of the main problems of modern hepatology. There are many variants of treatment, but there is no common opinion about scheme and time of onset of the therapy. From the other hand, early treatment can prevent chronisation in more than 70% of cases. Specific therapy was used 135 patients with acute hepatitis C aged from 16 to 52 years (26,5+0,7 years). Our analysis has shown, that its better to start specific therapy on the second month of the disease with -interferon monotherapy by induction scheme.

Treatment of acute hepatitis C remains one of the main problems of modern hepatology. There are many variants of treatment, but there is no common opinion about scheme and time of onset of the therapy. From the other hand, early treatment can prevent chronisation in more than 70% of cases. Specific therapy was used 135 patients with acute hepatitis C aged from 16 to 52 years (26,5+0,7 years). Our analysis has shown, that its better to start specific therapy on the second month of the disease with -interferon monotherapy by induction scheme.

acute hepatitis Cantiviral therapyinduction treatment schemeacute hepatitis Cantiviral therapyinduction treatment schemeReferencesJackel, E. The course and therapy of acute hepatitis C viral infection. Is a prevention of its becoming chronic possible? / . Jackel, M.P. Manns // Z. Gastroenterol. – 2000. – № 38. – P. 387–395.Jackel, E. The course and therapy of acute hepatitis C viral infection. Is a prevention of its becoming chronic possible? / . Jackel, M.P. Manns // Z. Gastroenterol. – 2000. – № 38. – P. 387–395.Gerlach, T.J. Acute hepatitis C: Natural course and response to antiviral treatment / T.J. Gerlach [et al.] /Hepatology. – 2001. – № 34. – P. 341.Gerlach, T.J. Acute hepatitis C: Natural course and response to antiviral treatment / T.J. Gerlach [et al.] /Hepatology. – 2001. – № 34. – P. 341.Wedemeyer, H. Whom? When? How? Another piece of evidence for early treatment of acute hepatitis C / H. Wedemeyer [et al.] // Hepatology. – 2004. – № 39. – P. 1201–1203.Wedemeyer, H. Whom? When? How? Another piece of evidence for early treatment of acute hepatitis C / H. Wedemeyer [et al.] // Hepatology. – 2004. – № 39. – P. 1201–1203.Бакулин, И.Г. Актуальные вопросы противовирусной терапии хронических гепатитов В и С / И.Г. Бакулин // Эксперим. и клинич. гастроэнтерология. – 2010. – № 5. – С. 3–9.Бакулин, И.Г. Актуальные вопросы противовирусной терапии хронических гепатитов В и С / И.Г. Бакулин // Эксперим. и клинич. гастроэнтерология. – 2010. – № 5. – С. 3–9.Magnia, A. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial / A. Magnia [et al.] // Hepatology. – 2008. – № 47. – P. 43–50.Magnia, A. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial / A. Magnia [et al.] // Hepatology. – 2008. – № 47. – P. 43–50.Wiegand, J. Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon alpha / J. Wiegand [et al.] // J. Antimicrob Chemother. – 2008. – № 62. – P. 860–865.Wiegand, J. Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon alpha / J. Wiegand [et al.] // J. Antimicrob Chemother. – 2008. – № 62. – P. 860–865.Конусова, В.Г. Изменение показателей оксидантного и цитокинововго статуса больных хроническим гепатитом С и В при лечении препаратом рекомбинантного интерлейкина 1β человека / В.Г. Конусова [и др.] // Цитокины и воспаление. – 2003. – Т. 2, № 1. – С. 20–28.Конусова, В.Г. Изменение показателей оксидантного и цитокинововго статуса больных хроническим гепатитом С и В при лечении препаратом рекомбинантного интерлейкина 1β человека / В.Г. Конусова [и др.] // Цитокины и воспаление. – 2003. – Т. 2, № 1. – С. 20–28.

The authors declare that there are no conflicts of interest present.